Briacell Therapeutics Corp T.BCT

Alternate Symbol(s): BCTX | BCTXW

Healthcare Biotechnology

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.

TSX:BCT - Post by User

Briacell Therapeutics Corp

Bullboard Posts

Comment by Pugsrock2on Apr 07, 2017 8:00pm

206 Views

Post# 26094689

RE:RE:RE:RE:RE:Briacell has a government identifier for new trial!!

even if they do get 1 patient (which is a long ways from the 24 that should have already been completely through the trial ) we probably won't hear any results until the end of the year so stock price will drift into oblivion and more likely than not the descent will be accelerated by a news release detailing some lame explanation why the trial will be delayed until 1st or 2nd quarter of 2018

Bullboard Posts

Sirios Resource discovers visible gold in Quebec